martes, 12 de mayo de 2015

National Guideline Clearinghouse | Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA 142).

full-text ►

National Guideline Clearinghouse | Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA 142).



National Institute for Health and Care Excellence (NICE)

National Guideline Clearinghouse (NGC)

Guideline Title
Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA 142).
Bibliographic Source(s)
National Institute for Health and Care Excellence (NICE). Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142). London (UK): National Institute for Health and Care Excellence (NICE); 2014 Nov. 47 p. (Technology appraisal guidance; no. 323). 
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 May. 36 p. (Technology appraisal guidance; no. 142)
This guideline meets NGC's 2013 (revised) inclusion criteria.

No hay comentarios:

Publicar un comentario